NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

被引：0

作者：

Vilde Drageset Haakensen

Anna K. Nowak

Espen Basmo Ellingsen

Saima Jamil Farooqi

Maria Moksnes Bjaanæs

Henrik Horndalsveen

Tine Mcculloch

Oscar Grundberg

Susana M. Cedres

Åslaug Helland

机构：

[1] Oslo University Hospital,Department of Oncology

[2] Oslo University Hospital,Department of Cancer Genetics, Institute for Cancer Research

[3] University of Western Australia,National Centre for Asbestos Related Diseases, Institute for Respiratory Health

[4] Sir Charles Gairdner Hospital,Department of Medical Oncology

[5] Oslo University Hospital,Department of Tumor Biology, Institute for Cancer Research

[6] Ultimovacs,Department of Oncology and Clinical Cancer Research Center

[7] Aalborg University Hospital,Department of Clinical Medicine, Faculty of Medicine

[8] Aalborg University,Thoracic Oncology Center, Theme Cancer

[9] Karolinska University Hospital,Oncology Department

[10] Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology,Faculty of Medicine

[11] University of Oslo,undefined

来源：

Journal of Translational Medicine | / 19卷

关键词：

Malignant pleural mesothelioma; Telomerase vaccine; Immunotherapy; hTERT; Nivolumab; Ipilimumab; Biomarker; Immune response;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
Haakensen, Vilde Drageset
Nowak, Anna K.
Ellingsen, Espen Basmo
Farooqi, Saima Jamil
Bjaanaes, Maria Moksnes
Horndalsveen, Henrik
Mcculloch, Tine
Grundberg, Oscar
Cedres, Susana M.
Helland, Aslaug
JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
[2] Nivolumab and Ipilimumab +/-UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study)
Haakensen, V.
Nowak, A.
Ellingsen, E.
Grundberg, O.
Farooqi, S.
Mcculloch, T.
Cedres, S.
Bjaanaes, M.
Helland, A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S380 - S380
[3] UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial
Haakensen, Vilde Drageset
Ojlert, Asa Kristina
Thunold, Solfrid
Farooqi, Saima
Nowak, Anna K.
Chin, Wee L.
Grundberg, Oscar
Szejniuk, Weronika Maria
Cedres, Susana
Sorensen, Jens Benn
Dalen, Tonje Sofie
Lund-Iversen, Marius
Bjaanaes, Maria
Helland, Aslaug
EUROPEAN JOURNAL OF CANCER, 2024, 202
[4] Ipilimumab and Nivolumab in the Treatment of Recurrent Malignant Pleural Mesothelioma: A Phase II Study
Disselhorst, M.
Harms, E.
Van Tinteren, H.
Quispel-Janssen, J.
Monkhorst, K.
Burgers, S.
Baas, P.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1746 - S1746
[5] A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)
Goto, Y.
Okada, M.
Kijima, T.
Aoe, K.
Kato, T.
Fujimoto, N.
Nakagawa, K.
Takeda, Y.
Hida, T.
Kanai, K.
Imamura, F.
Oizumi, S.
Takahashi, T.
Takenoyama, M.
Tanaka, H.
Ohe, Y.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1883 - S1883
[6] Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study
Namikawa, Kenjiro
Kiyohara, Yoshio
Takenouchi, Tatsuya
Uhara, Hisashi
Uchi, Hiroshi
Yoshikawa, Shusuke
Takatsuka, Sumiko
Koga, Hiroshi
Wada, Naoko
Minami, Hironobu
Hatsumichi, Masahiro
Asada, Suguru
Namba, Yoshinobu
Yamazaki, Naoya
EUROPEAN JOURNAL OF CANCER, 2018, 105 : 114 - 126
[7] Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study
Calabro, Luana
Morra, Aldo
Giannarelli, Diana
Amato, Giovanni
D'Incecco, Armida
Covre, Alessia
Lewis, Arthur
Rebelatto, Marlon C.
Danielli, Riccardo
Altomonte, Maresa
Di Giacomo, Anna Maria
Maio, Michele
LANCET RESPIRATORY MEDICINE, 2018, 6 (06) : 451 - 460
[8] Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Nathan, Paul
Ascierto, Paolo A.
Haanen, John
Espinosa, Enrique
Demidov, Lev
Garbe, Claus
Guida, Michele
Lorigan, Paul
Chiarion-Sileni, Vanna
Gogas, Helen
Maio, Michele
Fierro, Maria Teresa
Hoeller, Christoph
Terheyden, Patrick
Gutzmer, Ralf
Guren, Tormod K.
Bafaloukos, Dimitrios
Rutkowski, Piotr
Plummer, Ruth
Waterston, Ashita
Kaatz, Martin
Mandala, Mario
Marquez-Rodas, Ivan
Munoz-Couselo, Eva
Dummer, Reinhard
Grigoryeva, Elena
Young, Tina C.
Schadendorf, Dirk
EUROPEAN JOURNAL OF CANCER, 2019, 119 : 168 - 178
[9] Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Chesney, Jason
Puzanov, Igor
Collichio, Frances
Singh, Parminder
Milhem, Mohammed M.
Glaspy, John
Hamid, Omid
Ross, Merrick
Friedlander, Philip
Garbe, Claus
Logan, Theodore F.
Hauschild, Axel
Lebbe, Celeste
Chen, Lisa
Kim, Jenny J.
Gansert, Jennifer
Andtbacka, Robert H. I.
Kaufman, Howard L.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1658 - +
[10] Long-Term Efficacy and Safety of Nivolumab in Second- or Third-Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study)
Nakano, T.
Okada, M.
Kijima, T.
Aoe, K.
Kato, T.
Fujimoto, N.
Nakagawa, K.
Takeda, Y.
Hida, T.
Kanai, K.
Imamura, F.
Oizumi, S.
Takahashi, T.
Takenoyama, M.
Tanaka, H.
Ohe, Y.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S338 - S338

← 1 2 3 4 5 →